TMCnet News
Excision BioTherapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
SAN FRANCISCO, April 10, 2024 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, Inc. (“Excision”, the “Company”), a clinical-stage biotechnology company developing CRISPR-based therapies to cure serious latent viral infectious diseases, today announced presentation of six abstracts at the ASGCT 2024 Annual Meeting, which is being held from May 7-11, 2024 in Baltimore, Maryland. The presentations are related to new data for the Company’s emerging preclinical programs for herpes simplex virus-1 keratitis (HSV-1 Keratitis) and hepatitis B virus (HBV), as well as an overview of a next generation AAV delivery vector. In addition, there will be an update on the Company’s first-in-human study of EBT-101. Presentation details: Oral Presentations Title: Non-Viral Gene Editing with Dual Guide RNAs for Chronic Hepatitis B Infection Title: Selecting highly conserved and specific guide RNAs for CRISPR/CasX-mediated gene editing of the HSV-1 genome Location: Ballroom 3 Date/Time: May 10, 2024, 2:00 to 2:15 pm (EST) Title: EBT-101: First-in-human clinical trial of systemic CRISPR-CA9 multiplex targeting of Latent HIV Presentation details: Poster Presentations Title: CRISPR/CasX-Mediated Gene Editing as a Therapeutic Approach for HSV-1 Keratitis Title: Develop Next Generation All-in-One AAV Vectors for CRISPR/Cas Gene Editing with Paired Guide RNAs Title: CRISPR/Cas9-mediated gene editing for herpes simplex virus reduces viral reactivation in a latent rabbit keratitis model About Excision BioTherapeutics, Inc. Excision BioTherapeutics, Inc. develops CRISPR-based medicines as potential cures for serious viral latent infectious diseases based its proprietary multiplexed gene editing platform that unites next-generation CRISPR nucleases with a novel gene editing approach to develop curative therapies. The Company’s pipeline targets large, underserved markets including herpes simplex virus-1 keratitis (HSV-1 keratitis), hepatitis B virus (HBV) and human immunodeficiency virus-1 (HIV-1). Excision’s foundational technologies were developed in the laboratories of Dr. Kamel Khalili at Temple University and Dr. Jennifer Doudna at the University of California, Berkeley. For more information, please visit www.excision.bio. Contact: |